REFRACTORY COLORECTAL ADENOCARCINOMA
Clinical trials for REFRACTORY COLORECTAL ADENOCARCINOMA explained in plain language.
Never miss a new study
Get alerted when new REFRACTORY COLORECTAL ADENOCARCINOMA trials appear
Sign up with your email to follow new studies for REFRACTORY COLORECTAL ADENOCARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for stubborn colon cancer: three-drug combo enters early testing
Disease control TerminatedThis early-phase study tests whether adding an experimental drug (ZEN003694) to two approved cancer drugs (cetuximab and encorafenib) is safe and effective for people with a specific type of advanced colorectal cancer (BRAF V600E) that has spread and no longer responds to standar…
Matched conditions: REFRACTORY COLORECTAL ADENOCARCINOMA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 15, 2026 11:55 UTC
-
New hope for advanced colon cancer patients who stopped responding to standard treatments
Disease control OngoingThis study tests two drugs, panitumumab and trametinib, in 59 people with stage IV colorectal cancer that no longer responds to standard therapies. Panitumumab helps the immune system attack cancer cells, while trametinib blocks enzymes that help tumors grow. The goal is to see i…
Matched conditions: REFRACTORY COLORECTAL ADENOCARCINOMA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated May 13, 2026 16:02 UTC